|
ObjectiveTo detect the expression of ERCC1 in the tissue of Non-Hodgkin’s Lymphoma with the help of Immunohistochemical techniques; To investigate premilinarily the relationship between ERCCI and pathological types, clinical phenotype, short term effects and hemotological toxicity of the population of non-hodgkin’s lymphoma. MethodsThis study included 108 cases of newly-diagnosed NHL victims which were confirmed by pathologic examinations in attached tumor hospital of Guangxi Medical Univeresity. Related data were collected as gender, age, pathologic types, existence of B symptom, staging, LDH level and numbers of extranodal involvement, and then detected the expression of ERCC1 in the tissue of Non-Hodgkin’s Lymphoma of the 108 cases. SPSS18.0 was applied to perform statistic analysis. Results1. Positive expression of ERCC1 protein in NHL tissue mainly existed in nuclei as yellow particles. These were 51 of 108 cases had ERCC1 positive , and the positive expression rate of ERCC1 protein in NHL was 47.2%(51/108).2. In subgroups of different gender、age and peoples, there was no significant difference of the positive expression rate of ERCC1 protein (P>0.05). 3. In subgroups of T cell NHL, B cell NHL or other cell NHL, the positive expression rate of ERCC1 protein pronounced no significant difference. (P>0.05). However, the positive expression rate of ERCC1 protein in giant mass group was 75.0%, significantly higher than that of non-giant mass group (42.9%). The positive expression rate of ERCC1 protein in subgroups of different Ann Arbor staging、International Prognosis Index (IPI) was not significant (P>0.05).In IPI subgroup stratified analysis, the positive expression rate of ERCC1 protein had no strong correlation with existence of extrnodal involvement, numbers of extranodal involvement and different levels of LDH.4.The relation between the expression of ERCC1 protein and short-term therapeutic effectIn groups of different therapeutic effects, as CR group、PR group、SD group and PD group, the positive expression rate of ERCC1 protein was 44.1%、48.7%、38.5% and 70.0% ,respectively, with no significant statistic difference (P>0.05). In CR+PR subgroup, the positive expression rate of ERCC1 protein was 46.6%, which was lower than that of SD+PD subgroup(52.2%), but there was no significant difference( P=0.639).In the patients of the chemotherapy cycles was or less than 4 cycles, the positive expression rate of ERCC1 protein in groups of CR group, PR group, SD group and PD group was 27.3%, 52.6%, 40.0%, 75.0%, respectively, with no significant statistic difference (P>0.206); the positive expression rate of ERCC1 protein in the group of CR+PR and SD+PD group were 43.3% and 50%, respectively, with no markedly difference(P=0.679). In the patients of the chemotherapy cycles was more than 4 cycles, the positive expression rate of ERCC1 protein in groups of CR group, PR group, SD group and PD group was 52.1%, 42.1%, 33.3%, 66.7%, respectively, with no significant difference (P=0.794); the positive expression rate of ERCC1 protein in the group of CR+PR and SD+PD group was 47.6% and 55.9%, respectively (P=0.726).In stratified analysis of 43 casee of B cell NHL which received CHOP regimen, the positive expression rate of ERCC1 protein in CR+PR subgroup was 45.7%, which was lower than that of SD+PD subgroup(62.5%), but there was not significant difference ( P=0.391).In stratified analysis of 20 casee of T cell NHL which received CHOP regimen, the positive expression rate of ERCC1 protein in CR+PR subgroup was 60.0%, which was higher than that of SD+PD subgroup(20.0%), and there was not significantly different ( P=0.303).5. The relation between the expression of ERCC1 protein and NHL chemotherapy related hematological toxicityIn groups of normal WBC count and decreased WBC count, normal neutrophili count and decreased neutrophili count, and normal platelet count and decreased platelet count, respectively, the positive expression rate of ERCC1 protein had no significant difference.Hematological toxicity was divided into I-II degree subgroup and III-IV degree subgroup according to WBC, or neutrophili, or HGB, or platelet, respectively, the positive expression rate of ERCC1 protein was not significantly different between I-II degree subgroup and III-IV degree subgroup. Conclusion1. The positive expression rate of ERCC1 protein had no marked correlation with patients’gender, age or people.2. The positive expression rate of ERCC1 protein had no significant difference between subgroups divided based on its clinicopathological staging or IPI scoring, but it was correlated with the size of NHL mass, the positive expression rate of ERCC1 protein was significantly higher in huge mass NHL than non-huge mass NHL, which suggested ERCC1 could be an index of predicting the malignance of NHL.3. The positive expression rates of ERCC1 protein in subgroups responding well to chemotherapy were lower than those responding ill to chemotherapy, but there was no significant difference, which revealed the relationship between ERCC1 and first line chemotherapy for NHL needed further research.4. The positive expression rate of ERCC1 protein had no correlation with chemotherapy-related hematological toxicity.
|